GleamWall
中文EN

OLMA Olema Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1750284 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-69.8%
ROA-59.5%
ROIC (approx.)-67.3%
Asset turnover—

Leverage & solvency

Liabilities / assets16.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$67.60M$57.78M$49.23M$43.22M$39.95M$43.90M$30.62M$32.30M
SG&A expense$9.93M$9.39M$8.75M$6.86M$5.93M$3.96M$4.25M$4.47M
Operating income-$77.53M-$67.18M-$57.99M-$50.08M-$45.88M-$47.86M-$34.87M-$36.77M
Net income-$73.60M-$63.20M-$53.09M-$46.06M-$42.22M-$43.78M-$30.39M-$33.57M
EBITDA-$77.43M-$67.08M-$57.87M-$49.90M-$45.83M-$47.73M-$34.74M-$36.65M
EPS (basic)-0.73-0.61-0.52—-0.49-0.51-0.36—
EPS (diluted)-0.73-0.61-0.52—-0.49-0.51-0.36—
Weighted avg. shares (diluted)101.09M104.45M102.80M—85.73M85.50M85.43M—
Balance sheet
Cash & equivalents$47.52M$48.60M$52.55M$48.30M$35.26M$52.47M$50.64M$139.48M
Short-term investments$366.25M$412.47M$452.80M$457.14M$293.70M$309.44M$342.07M$294.61M
Current assets$423.43M$469.88M$513.23M$515.45M$334.33M$367.73M$396.66M$438.47M
PP&E, net$1.65M$382,000$356,000$274,000$486,000$560,000$653,000$746,000
Total assets$441.07M$486.58M$530.64M$533.43M$352.45M$382.00M$409.64M$450.98M
Current liabilities$69.23M$53.01M$47.17M$51.80M$41.66M$33.16M$26.06M$41.76M
Total liabilities$72.23M$56.01M$50.17M$54.87M$44.97M$36.77M$26.19M$42.02M
Shareholders' equity$368.84M$430.56M$480.48M$478.56M$307.49M$345.24M$383.45M$408.96M
Shares outstanding87.54M87.45M87.33M81.38M68.65M68.63M68.33M74.31M
Cash flow statement
Operating cash flow-$47.11M-$45.90M-$45.99M-$38.33M-$34.53M-$29.88M-$43.98M-$26.28M
Capital expenditure$900,000———$0——$0
Free cash flow-$48.01M———-$34.53M——-$26.28M
Investing cash flow$45.60M$40.84M$4.53M-$162.18M$17.27M$34.23M-$45.08M-$114.42M
Financing cash flow$434,000$1.11M$45.70M$213.55M$41,000-$2.52M$222,000$244.30M
Depreciation & amortization$94,000$102,000$119,000$187,000$43,000$132,000$128,000$116,000
Stock-based compensation$12.08M$12.90M$10.15M$4.27M$4.25M$4.69M$4.38M$6.32M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.